Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat^® Soft Mist^™ Inhaler

Abstract

Current guidelines for the management of chronic obstructive pulmonary disease (COPD) recommend the regular use of inhaled bronchodilator therapy in order to relieve symptoms and prevent exacerbations. A variety of inhaler devices are currently available to COPD patients, and the choice of device is an important consideration because it can influence patients’ adherence to treatment, and thus potentially affect the long-term outcome. The Respimat^® Soft Mist^™ Inhaler (SMI) generates a slow-moving aerosol with a high fine particle fraction, resulting in deposition of a higher proportion of the dose in the lungs than pressurized metered-dose inhalers (pMDIs) or some dry powder inhalers (DPIs). We review clinical studies of inhaler satisfaction and preference comparing Respimat^® SMI against other inhalers in COPD patients. Using objective and validated patient satisfaction instruments, Respimat^® SMI was consistently shown to be well accepted by COPD patients, largely due to its inhalation and handling characteristics. In comparative studies with pMDIs, the patient total satisfaction score with Respimat^® SMI was statistically and clinically significantly higher than with the pMDI. In comparative studies with DPIs, the total satisfaction score was statistically significantly higher than for the Turbuhaler^® DPI, but only the performance domain of satisfaction was clinically significantly higher for Respimat^® SMI. Whether the observed higher levels of patient satisfaction reported with Respimat^® SMI might be expected to result in improved adherence to therapy and thus provide benefits consistent with those recently shown to be associated with sustained bronchodilator treatment in patients with COPD remains to be proven.

Keywords:

• Respimat^® Soft Mist^™ Inhaler
• pressurized metered-dose inhalers
• pressurized metered-dose inhalers
• inhaler devices

Acknowledgments and Disclosures

The authors would like to acknowledge the help of Roger Nutter (Lexeme) and David Macari (PAREXEL MMS Ltd) for their assistance in drafting this paper, which was funded jointly by Boehringer Ingelheim and Pfizer.

Respimat^® and Soft Mist^™ are trade marks of the Boehringer Ingelheim group of companies. Turbuhaler^® is a trade mark of the AstraZeneca group of companies. Diskus^® is a trade mark of GlaxoSmithKline group of companies.

Drs Hodder and Price have received speakers’ honoraria, consulting fees and research grants from various pharmaceutical companies including Boehringer Ingelheim and Pfizer.